We study Gynecological cancer and the prevention of cervical cancer and osteoporosis. We evaluate self-sampling HPV analyses and other diagnostic methods such as methylation analyses in cervical cancer prevention. In ovarian and endometrial cancer, we search for biomarker panels and cell free DNA mutations as diagnostic and predictive markers. We study Quality of Life (QoL) and patient related experience measurement (PREM) during and after gynecological cancer treatment. The osteoporosis projects evaluate screening tools in prevention of osteoporosis. Societal impact: The self-sampling HPV projects has promoted the use of vaginal self-sample HPV analyses in non-attendee as well as recommendations to use self-samples screening in women during the Covid-pandemic. The plasma biomarker HE4 is nowadays used as a diagnostic marker in women with adnexal lesions. The FRAX screening instrument has been evaluated with promising result in prevention of osteoporosis.